Clinical Implications of <i>TP53</i> Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

Tariq Kewan(Yale University), Amer M. Zeidan(Yale Cancer Center), Gail J. Roboz(Cornell University), Maximilian Stahl(Harvard University), Hetty E. Carraway(Cleveland Clinic), David A. Sallman(Moffitt Cancer Center), Amy E. DeZern(Johns Hopkins University), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Eric Padron(Moffitt Cancer Center), Abhay Singh(Cleveland Clinic), Maria L. Amaya(University of Colorado Denver), Jessica M. Stempel(University of New Haven), Zhuoer Xie(Mayo Clinic), Ondřej Bláha(Yale University), Michael R. Savona(Vanderbilt University), Mikkael A. Sekeres(University of Miami), Namrata S. Chandhok(Sylvester Comprehensive Cancer Center), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Benjamin Rolles(Brigham and Women's Hospital), Hunter Cochran(Washington University in St. Louis), Rahul Ramaswamy(Vanderbilt University Medical Center), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Pinkal Desai(NewYork–Presbyterian Hospital), Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Jaroslaw P. Maciejewski(Cleveland Clinic), Matteo Giovanni Della Porta(Humanitas University), Rory M. Shallis(Smilow Cancer Hospital), Amyah C. Harris(Harvard University), Andrew M. Brunner(Harvard University), Najla H. Al Ali(Moffitt Cancer Center), Rami S. Komrokji(Moffitt Cancer Center)
Blood
November 2, 2023
Cited by 1


Related Papers